Literature DB >> 19362580

Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations.

Giovanna Albertin1, Diego Guidolin, Elisa Sorato, Raffaella Spinazzi, Alessandra Mascarin, Barbara Oselladore, Monica Montopoli, Michele Antonello, Domenico Ribatti.   

Abstract

Urotensin-II (U-II), along its receptor UT, is widely expressed in the cardiovascular system, where it exerts regulatory actions under both physiological and pathological conditions. In the present study, human vascular endothelial cells (EC) from one arterious and three venous vascular beds were used to investigate in vitro their heterogeneity in terms of expression of U-II and UT and of angiogenic response to the peptide. Real-time PCR and immunocytochemistry demonstrated the expression of UT, as mRNA and protein, in all the EC populations investigated. U-II, on the contrary, was detectable only in EC from aorta and umbilical vein. U-II did not affect the proliferation rate of adult human EC, but induced a moderate proliferative effect on EC from human umbilical vein. When tested in the Matrigel assay, however, all EC exhibited a strong angiogenic response to the peptide, comparable to that of fibroblast growth factor-2 (FGF-2) and it was not associated to an increased expression of vascular endothelial growth factor (VEGF) and/or its receptors. The angiogenic effect of U-II was abolished by the UT antagonist palosuran. Overall, these data suggest that U-II, in addition to the well known role in the regulation of cardiovascular function, also exert a specific angiogenic activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19362580     DOI: 10.1016/j.regpep.2009.04.006

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  5 in total

1.  Urotensin inhibition with palosuran could be a promising alternative in pulmonary arterial hypertension.

Authors:  Ahmet Mesut Onat; Yavuz Pehlivan; Ibrahim Halil Turkbeyler; Tuncer Demir; Davut Sinan Kaplan; Ali Osman Ceribasi; Mustafa Orkmez; Ediz Tutar; Seyithan Taysi; Mehmet Sayarlioglu; Bunyamin Kisacik
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

2.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

Review 3.  The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.

Authors:  Hélène Castel; Laurence Desrues; Jane-Eileen Joubert; Marie-Christine Tonon; Laurent Prézeau; Marie Chabbert; Fabrice Morin; Pierrick Gandolfo
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-25       Impact factor: 5.555

4.  Urotensin II induces interleukin 8 expression in human umbilical vein endothelial cells.

Authors:  Chung-Yi Lee; Yi-Tin Tsai; Shih-Hurng Loh; Ju-Chi Liu; Tso-Hsiao Chen; Hung-Hsing Chao; Tzu-Hurng Cheng; Jin-Jer Chen
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

5.  An easy-to-handle microfluidic device suitable for immunohistochemical procedures in mammalian cells grown under flow conditions.

Authors:  C Fede; I Fortunati; L Petrelli; D Guidolin; R De Caro; C Ferrante; G Albertin
Journal:  Eur J Histochem       Date:  2014-05-12       Impact factor: 3.188

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.